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Review article
Completeness of reporting of
randomised controlled trials including
people with transient ischaemic attack
or stroke: A systematic review
Blair Wilson1, Peter Burnett2, David Moher3,
Douglas G Altman4 and Rustam Al-Shahi Salman5
Abstract
Purpose: To assess the adherence of stroke randomised controlled trials to Consolidated Standards Of Reporting
Trials reporting guidelines and investigate the factors that are associated with completeness of reporting.
Method: We took a random sample from the Cochrane Stroke Group’s Trial Register of transient ischaemic attack or
stroke randomised controlled trials, published in English in 1997–2016 inclusive. Two reviewers assessed the published
report of the final primary results of stroke randomised controlled trials with a 10-point truncated Consolidated
Standards Of Reporting Trials reporting checklist to investigate adherence over time, univariable associations and
independent associations with total Consolidated Standards Of Reporting Trials reporting score in a multiple linear
regression model.
Findings: In this random sample of 177 stroke randomised controlled trials, the mean score on the truncated
Consolidated Standards Of Reporting Trials checklist was 5.8 (SD 2.2); reporting improved from 1997–2000 (4.9 SD
2.0) to 2001–2009 (5.8 SD 2.1) and to 2010–2016 (6.8 SD 2.1). A higher Consolidated Standards Of Reporting Trials
score was independently associated with publication during epochs following a revision of Consolidated Standards Of
Reporting Trials reporting guidelines (p< 0.001), journal endorsement of the Consolidated Standards Of Reporting
Trials reporting guideline at the time of randomised controlled trial publication (p< 0.001) and modified journal impact
factor using median citation distribution (p¼ 0.012).
Discussion: Stroke randomised controlled trial reporting to Consolidated Standards Of Reporting Trials standards has
improved over time, but could be better.
Conclusion: Journal endorsement and enforcement of Consolidated Standards Of Reporting Trials reporting guidelines
could further improve the reporting of stroke randomised controlled trials.
Systematic review registration: Registered with PROSPERO (CRD42017072193).
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Introduction
Randomised controlled trials (RCTs) are the fairest
tests of treatment, but judgements about their value
are dependent on transparent and complete reporting.
Inadequate reporting prevents a complete assessment
of an RCT’s risk of bias and description of their results,
which can also preclude the re-use of data in meta-
analyses.1,2 In order to combat this, the Consolidated
Standards Of Reporting Trials (CONSORT) Statement
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was developed in 1996,3 updated in 20014 and revised
in 20105 to improve the reporting of RCTs. The
CONSORT guidelines seem to have been endorsed by
over 600 journals.6
In general, studies of RCT reporting have not only
demonstrated incomplete reporting in numerous spe-
cialties but also modest improvements over time that
were often associated with journal endorsement and
uptake of CONSORT.7–20 Concerns about complete-
ness of reporting remain, particularly in journals with
low impact factors.7,21
Despite advances in the prevention and treatment of
stroke supported by RCTs, stroke remains the leading
cause of disability and second leading cause of death
worldwide and stroke burden is projected to increase
with changes in lifestyle and longevity.22,23 The limited
funding available for stroke research to lessen this
burden should not be wasted.24,25 But concerns
remain about waste in stroke research, including the
poor reporting of research.26,27
Other than an investigation of the reporting of a
specific intervention for stroke rehabilitation,28 the
last systematic assessment of stroke RCT reporting
pre-dated CONSORT.9 That review found that the
standard of reporting was poor, but it improved over
time alongside an increase in RCT sample size.
Reporting did not appear to be associated with journal
impact factor but trials with a positive outcome tended
to be less well reported than those with neutral or neg-
ative outcomes.9 This differs from the findings in other
specialties.14,15 However, it is unclear whether stroke
RCT reporting has improved since CONSORT guide-
lines were released and updated, what factors are asso-
ciated with better reporting, and whether these
associations differ from other diseases.27
Therefore, we aimed to assess: the extent to which
the published reports of the final primary results of
RCTs involving participants with transient ischaemic
attack (TIA) or stroke have adhered to the
CONSORT reporting guidelines between 1997 and
2016; whether adherence has changed over time, in par-
ticular following each revision of the CONSORT
guidelines; and which factors are associated with
better reporting.
Methods
Protocol and registration
All authors developed and approved the protocol,
which we registered with PROSPERO before embark-
ing on data collection (CRD42017072193).
Eligibility criteria
We included published reports of the final primary
results of RCTs including patients with TIA or
stroke, published in 1997–2016 inclusive. We applied
eligibility criteria designed to obtain a representative
sample of RCTs (Table 1).
Information sources
On 30 August 2017, the Managing Editor of the
Cochrane Stroke Group searched the Cochrane
Stroke Group’s Trial Register for all publications of
RCTs including patients with TIA or any type of
stroke published in 1997–2016 inclusive.
Study selection. We sub-divided the results of the search
into three epochs of publication (1997–2000, 2001–2009
or 2010–2016), each corresponding to the timing of a
published revision of the CONSORT guidelines.3,5,29
We used a random number generator in Microsoft
Excel to take a random sample of equal size from
each of these three groups of RCTs, removed duplicate
records of the same RCT in order to include only the
report of the final primary results of each RCT, and
took further random samples as required to achieve
our target sample size of 180 RCTs. We chose this
sample size so that it would adequately power a multi-
ple regression analysis including 10 covariates based on
the likely distribution of CONSORT reporting scores
and be feasible for two reviewers to assess in the time
available to the research team.
Table 1. Eligibility criteria for included studies.
Inclusion criteria Exclusion criteria
Published report of the final primary results of an
RCT, published in 1997–2016 inclusive
English language publication
Participants included after TIA or any type of stroke
Any type of therapeutic intervention (drug, surgery,
device, rehabilitation, etc.)
Reports of interim analyses that preceded the report of the final
primary results of an RCT
Reports of secondary or long-term follow-up analyses of an RCT
Duplicate reports of the final primary results of an RCT
Cost-effectiveness and economic studies of an RCT
RCTs in which stroke was not the qualifying condition, but
the outcome
RCT: randomised controlled trial.
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Data collection
We imported the results of the search into Covidence
(www.covidence.org). One reviewer (BW) screened the
titles and abstracts of all RCTs to exclude any ineligible
RCTs. Two reviewers (PB and BW) reviewed the full
text of potentially eligible RCTs, independent of each
other. PB and BW used the data collection tool within
Covidence to independently assess the completeness of
reporting of included RCTs. Any protocols that were
referenced within the included papers were checked and
included in the scoring. PB and BW used Microsoft
Excel to extract information from each RCT on pre-
specified covariates that we hypothesised might be
associated with completeness of reporting. Any uncer-
tainties or disagreements about eligibility, completeness
of reporting, or covariates were resolved by discussion
with another reviewer (RA-SS).
Data items
Our primary outcome was a truncated version of the
CONSORT checklist comprising the 10 most impor-
tant CONSORT checklist items, identified by a group
of experts from within the CONSORT group, based on
their professional opinion and supported by empirical
evidence where available (Table 2).30 We tackled the
problem of partial reporting by adapting the wording
of some criteria so that each item could be scored 1 if it
was reported or 0 if it was not reported, for a total
score ranging from 0 to 10.
In our protocol, we specified the following covariates
to investigate associations with completeness of report-
ing based on prior evidence of their association with
completeness of reporting in other diseases: (1)
CONSORT endorsement by the journal preceding the
publication of the RCT (we established this by searching
the CONSORT database online, contacting the journal
or searching the journal’s archived guidelines);11–13,20
(2) year of publication;7–10 (3) sample size of the
RCT;8,9,14,21 (4) number of recruiting sites (single vs.
multicentre);8,9,14,21 (5) direction and statistical signifi-
cance of results with reference to aims/hypothesis (pos-
itive, neutral or negative);9,14,15 (6) type of intervention
(drug, surgical or other);15,21 (7) funding source
(academic/governmental/charitable vs. commercial vs.
other)14,21 and (8) journal impact factor.7,8,21
However, we did not use journal impact factor because
it is widely acknowledged to be a flawed metric as it is
the arithmetic mean of a highly skewed distribution of
citations and it is quoted to a higher level of precision
(three decimal places) than is warranted by the underly-
ing data,31 and hence we used a ‘modified journal impact
factor’ that uses the median – rather than the mean –
number of citations.32 We also pre-specified (9) TIA/
stroke type and (10) intervention type (acute, preven-
tion, rehabilitation), which we hypothesised might influ-
ence the completeness of reporting of stroke RCTs.
Risk of bias
We reduced bias in our assessments of completeness of
reporting and covariates of interest by two reviewers
Table 2. Checklist items used for the truncated CONSORT score.
Criterion Description
Outcomes Explicitly defined, pre-specified, primary outcome measure, including how and when they
were assessed
Sample size Justification for sample size
Sequence generation Methods used to generate random allocation sequence
Allocation concealment Explicitly state mechanism used to implement random allocation sequence (such as sealed enve-
lopes or electronic sequence generation, and block sizes) and describe any steps taken to conceal
the sequence until interventions were assigned (such as opaque nature of envelopes or a central
telephone/web allocation centre). A description of both of these aspects was required to score a
point. Where electronic sequence generation was used it had to be clear that this was concealed
from researchers, and not predictable, either with a statement or example describing the use of a
central allocation centre
Blinding Clear statement about whether or not anyone (for example, participants’ care providers or those
assessing outcomes) was blinded to interventions after assignment
Outcome estimation For the primary outcome (identified as above), results for each group, the estimated effect size and
its precision (i.e. 95% CI)
Harms Mentions any harms or unintended effects in each group, or statement of no adverse effects
Registration Registration number and the trial registry
Protocol Where the trial protocol can be accessed, if available
Funding Sources of funding and other support (such as supply of drugs) and role of funders
CONSORT: Consolidated Standards Of Reporting Trials.
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assessing them independently. We looked for evidence
of differences between reviewers, which might be sys-
tematic, by calculating the kappa statistic to assess the
inter-reviewer variability for each CONSORT checklist
item (Table 2).
Summary measure
We used the truncated CONSORT score, which was
the sum of the score of each of the 10 fields in the
truncated list (Table 2) as our summary measure.
Statistical analysis
We assessed trends in trial characteristics with time
using the Cochran–Armitage test for trend. We quan-
tified the mean and SD of the truncated CONSORT
score. We assessed associations of categorical covari-
ates with truncated CONSORT score using ANOVA
and univariable associations with continuous variables
using Spearman’s rank-order correlation. We assessed
trends in reporting of individual CONSORT items with
time using the Cochran–Armitage test for trend. We
entered all 10 covariates into a single multiple linear
regression model to investigate the association of
each of our covariates with total truncated
CONSORT score, after checking linearity of relation-
ships, multivariable normality, multi-collinearity, the
absence of auto-correlation and homoscedasticity. We
used IBM SPSS 24, with a¼ 0.05.
Results
Study selection
From 7813 studies in the Cochrane Stroke Group Trial
Register published in 1997–2016 inclusive, we random-
ly sampled 180 that appeared eligible and included 177
(Figure 1).
Characteristics of the included RCTs
The RCTs included a variety of combinations of TIA
or stroke sub-types, the most frequent being ischaemic
stroke alone (Table 3). Three-quarters of RCTs evalu-
ated acute interventions and almost two-thirds of the
interventions were drugs. Sample sizes ranged from
8 to 21,106 patients, median 99 (inter-quartile range
41–367). Roughly half of included RCTs reported sta-
tistically significant beneficial (i.e. ‘positive’) effects on
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Figure 1. PRISMA flow chart.
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their primary outcomes. Roughly one-fifth of included
RCTs received commercial funding. More than one-
third of the journals had not explicitly endorsed the
CONSORT statement to require complete RCT report-
ing to the CONSORT standard. There was a statisti-
cally significant downward trend in the proportion of
acute trials (p< 0.001), those investigating a pharma-
cological intervention (p¼ 0.002) and journals endors-
ing CONSORT (p¼ 0.014) over time (the latter due to
an increase in the number of open access journals in
recent times).
Inter-reviewer agreement
For all 10 items in the truncated CONSORT checklist,
inter-reviewer agreement was high, ranging from
j¼ 0.96 to 1.00 for individual items (online appendix).
Completeness of reporting
In all 177 RCTs, the mean total truncated CONSORT
score was 5.8 (SD 2.2) out of 10, (ranging from 1 to 10
in individual RCTs). Completeness of reporting of each
Table 3. Descriptive characteristics of included RCTs.
All 177
RCTs (%)
1997–2000,
n¼ 59 (%)
2001–2009,
n¼ 59 (%)
2010–2016,
n¼ 59 (%)
Type of TIA/stroke included
Any type 3 (2) 3 (5) 0 (0) 0 (0)
Intracerebral haemorrhage 20 (11) 5 (8) 6 (10) 7 (12)
Ischaemic stroke 84 (48) 30 (51) 29 (49) 25 (42)
Sub-arachnoid haemorrhage 46 (26) 16 (27) 15 (25) 15 (25)
TIA 6 (3) 0 (0) 1 (2) 6 (10)
TIA or ischaemic stroke 12 (7) 3 (5) 6 (10) 3 (5)
Unknown 5 (3) 2 (3) 1 (2) 2 (3)
Type of RCT
Acute 131 (74) 53 (90) 45 (76) 35 (59)
Prevention 10 (6) 0 (0) 2 (3) 8 (14)
Rehabilitation 32 (18) 6 (10) 10 (17) 16 (27)
Other 4 (2) 0 (0) 2 (3) 0 (0)
Type of intervention
Drug 112 (63) 47 (80) 34 (58) 31 (53)
Surgical 44 (25) 6 (10) 10 (17) 5 (8)
Other 21 (12) 6 (10) 15 (25) 23 (39)
Number of recruiting sites
Multicentre 87 (49) 32 (54) 26 (44) 29 (49)
Single centre 82 (46) 25 (42) 30 (51) 27 (46)
Unknown 8 (5) 2 (3) 3 (5) 3 (51)
Sample sizea
Median (IQR) 99 (41–367) 142 (32–407) 90 (40–365) 94 (50–233)
RCT outcome
Positive (p< 0.05) 92 (52) 26 (44) 28 (47) 27 (46)
Neutral 78 (44) 30 (51) 27 (46) 30 (51)
Negative 7 (4) 2 (3) 4 (7) 2 (3)
Funding source
Not specified 66 (37) 24 (41) 26 (44) 16 (27)
Commercial 35 (20) 16 (27) 11(19) 8 (14)
Other 76 (43) 19 (32) 22 (37) 35 (59)
Journal endorsed CONSORT
Endorsed 108 (61) 43 (73) 35 (59) 30 (51)
Impact factora
Median (IQR) 4.2 (2.0–6.0) 4.8 (1.4–6.0) 5.2 (2.1–5.9) 3.0 (2.0–6.2)
Modified impact factora,b
Median (IQR) 2 (1–5) 2 (1–5) 3 (1–5) 2 (1–5)
TIA: transient ischaemic attack; IQR: inter-quartile range; RCT: randomised controlled trial; CONSORT: Consolidated Standards Of Reporting Trials.
aItems are reported as frequency (proportion) for categorical variables, unless otherwise specified for continuous variables.
bModified impact factor is the impact factor for the journal at the time of publication calculated using the median rather than mean of the citation
distribution.
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of the CONSORT items varied considerably (Figure 2).
Explicit definitions of the primary outcome measure
and the estimated treatment effect size and its precision
were most frequently reported and did not decrease
over time. Details of trial registration and the availabil-
ity of the protocol were least frequently reported, but
like many other items (other than harms and funding)
there was a statistically significant trend of increasing
completeness of reporting individual items over time.
Associations with completeness of reporting
In univariable analyses, there was a significant
improvement in total CONSORT score by 1.9 (95%
Confidence Interval (CI) 1.0–2.8) from 1997–2000
until 2010–2016 (p< 0.001) and by 1.1 (95% CI 0.2–
2.0) from 2001–2009 until 2010–2016 (p¼ 0.013)
(Table 4 and Figure 3). Journal endorsement of
CONSORT at the time of an RCT’s publication,
higher modified journal impact factor, having a com-
mercial funding source, multicentre recruitment and
larger sample size were all associated with higher
total CONSORT reporting scores (Table 4). In multi-
variable analysis, publication during epochs following
a revision of CONSORT reporting guidelines was
independently associated with higher completeness of
reporting (Table 5), as was journal endorsement of the
CONSORT reporting guideline at the time of RCT
publication, and journal modified impact factor.
Discussion
In this systematic review of 177 stroke RCTs published
over a 20-year period, we found that stroke RCTs on
average have reported 6 out of 10 items on a truncat-
ed CONSORT checklist (Figure 2). Encouragingly, the
overall completeness of reporting has increased with
time such that stroke RCTs published after the 2010
revision of CONSORT reported 7 out of 10 items
(Table 4). This improvement may reflect, at least in
part, the awareness or endorsement of CONSORT
guidelines by the International Committee of Medical
Journal Editors in 2001 and individual journals
since then.
The reporting of primary outcomes and estimates of
treatment effect on these outcomes have been consis-
tently good, while the least well-reported items were the
method of allocation concealment, trial registration
and protocol location (Figure 2), perhaps because
repositories for the latter two were not available in
the earlier epochs in this study.9,28 This is similar to
findings for trials in other diseases,8,11,16,21,28 although
the proportion of stroke RCTs adequately reporting
registration and the location of protocol is particularly
low. Each item that was poorly reported in 1997–2000,
excluding harms and funding, has shown an improve-
ment in completeness of reporting with time. The
reporting of harms appears to have decreased over
time, although this might be confounded by the
decrease in the proportion of stroke RCTs investigat-
ing drug or surgical interventions over time (Table 3),
in which the reporting of harms is more of a require-
ment than for other interventions (e.g. rehabilitation).
We did not find that the type of intervention was
associated with completeness of reporting in stroke
RCTs in contrast to previous studies in other sub-
specialties.15 The development and implementation of
extensions to the CONSORT statement, addressing the
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Table 4. Univariable analyses of associations with truncated CONSORT score.
Categorical covariates Number of RCTs
Mean total CONSORT score
(standard deviation) p
Year of publication <0.001
1997–2000 59 4.9 (2.0)
2001–2009 59 5.8 (2.1)
2010–2016 59 6.8 (2.1)
TIA/stroke typea 0.28
Haemorrhagic (ICH or SAH) 66 6.1 (2.1)
Ischaemic (all other groups) 111 5.7 (2.3)
Trial type 0.11
Acute 46 5.4 (2.3)
Other 131 6.0 (2.1)
Type of intervention 0.30
Drug 112 6.0 (2.2)
Other 65 5.6 (2.3)
Number of recruiting sites <0.001
Multicentre 87 6.6 (2.0)
Single centre/not specified 90 5.1 (2.1)
Outcome estimate 0.43
Positive 92 5.7 (2.3)
Negative or neutral 85 6.0 (2.1)
Funding source 0.022
Purely commercial 35 6.6 (1. 7)
Other/not specified 142 5.7 (2.3)
Journal endorsed CONSORT <0.001
Endorsed 108 6.6 (2.0)
Not endorsed 69 4.7 (2.0)
Continuous covariates Spearman rank-order coefficient p
Modified impact factor rs¼ 0.51 <0.001
Sample size rs¼ 0.38 <0.001
RCTs: randomised controlled trials; CONSORT: Consolidated Standards Of Reporting Trials.
aHaemorrhagic sub-category included intracerebral haemorrhage and subarachnoid haemorrhage, ischaemic encompassed all other sub-
categories as this was the most common sub-type within them.
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weaknesses in reporting of non-drug interventions, may
be responsible for this difference.33 Similar to the
results of others, this study has shown that the time
period of publication,7–10,14,15 journal endorsement of
CONSORT at the time of publication,11–13,20 and mul-
ticentre recruitment21 are all independently associated
with a higher completeness of reporting in stroke
RCTs. Others have also identified commercial funding
as being associated with better completeness of report-
ing.4,34,35 Our study used a modified journal impact
factor, which was associated with a higher total
CONSORT checklist score. This finding is in agree-
ment with those of recent studies,7,8,21 but in contrast
to the earlier stroke RCT study.9 We speculate that this
could be explained by the increased scrutiny and
stricter peer-review processes implemented by higher
impact journals in recent years, influenced by the
drive to improve completeness of reporting nowadays.2
Our study differs from the results of the only previous
study of the completeness of reporting of stroke RCTs,
which found that completeness of reporting was asso-
ciated with estimates of treatment effect.9
As far as we are aware this is the only study to assess
completeness of reporting and the associated factors
for stroke RCTs in the 21st century. However, it is
not without its weaknesses. We scored RCTs using a
modified, truncated CONSORT checklist, to give a
score out of 10 as a measure of completeness of report-
ing of key items. Each of the factors was weighted
equally, but these factors vary in their importance;
however, any attempt to implement a weighted
system to this list would be arbitrary and introduce a
degree of subjectivity which would limit the generalis-
ability of our results. An advantage of this binary scor-
ing system was the high inter-reviewer agreement in the
assessment of reporting. Other scoring systems are
Table 5. Multivariable linear regression analysis of associations with truncated CONSORT score.
Mean CONSORT
score (SD)
Multiple linear regression
RCTs (n) b Coefficient 95% CI p
Year of publication
1997–2000 59 4.9 (2.0) Ref
2001–2009 59 5.8 (2.1) 1.071 0.435 to 1.709 0.001
2010–2016 59 6.8 (2.1) 2.248 1.559 to 2.937 <0.001
TIA/stroke typea
Haemorrhagic 66 6.1 (2.1) Ref
Ischaemic 111 5.7 (2.3) 0.204 0.794 to 0.387 0.497
Trial type
Other 131 Ref
Acute 46 0.118 0.626 to 0.863 0.754
Type of intervention
Other 65 5.4 (2.3) Ref
Drug 112 6.0 (2.1) 0.098 0.505 to 0.702 0.748
Number of recruiting sites
Other 90 6.6 (2.0) Ref
Multicentre 87 5.1 (2.1) 0.672 0.132 to 1.211 0.015
Sample size
Per n¼100 increase 177 0.009 0.001 to 0.019 0.066
Outcome estimate
Negative or neutral 85 5.7 (2.3) Ref
Positive 92 6.0 (2.1) 0.216 0.722 to 0.290 0.400
Funding source
Other 142 6.6 (1. 7) Ref
Purely commercial 35 5.7 (2.3) 0.543 0.127 to 1.212 0.112
Journal endorsed CONSORT
Not endorsed 69 6.6 (2.0) Ref
Endorsed 108 4.7 (2.0) 1.382 0.726 to 2.038 <0.001
Modified impact factor
For each unit increase 177 0.127 0.028 to 0.226 0.012
RCTs: randomised controlled trials; CONSORT: Consolidated Standards Of Reporting Trials.
Multiple linear regression model adjusted for year of publication, TIA/stroke type, trial type, type of intervention, number of recruiting sites, sample
size, outcome estimate, funding source, CONSORTendorsement and modified impact factor. ‘Ref’ indicates which categories were used as reference
categories in the multiple linear regression.
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subject to lower and more variable kappa values, e.g.
ranging from 0.02 to 0.92.8 Lastly, some of our findings
may be confounded by factors relating to publication
culture: we found that lower impact factor journals
exhibited poorer reporting of RCTs, possibly reflecting
the fact that higher quality stroke RCTs may be first
submitted to higher impact factor journals.
In summary, the standard of reporting of stroke
RCTs has improved with time, but there is room for
improvement, particularly in lower impact factor jour-
nals. This study provides evidence for areas which can
be improved. Authors of stroke RCTs should focus on
better reporting of the method of allocation conceal-
ment, trial registration and protocol availability. The
independent associations that we found between
journal-level covariates and completeness of stroke
RCT reporting suggest that journals may be best
placed to improve reporting completeness by endorse-
ment and enforcement of the CONSORT checklist.
One study, but not all, shows that making adherence
to CONSORT guidelines mandatory improves com-
pleteness of reporting.36 We therefore suggest that jour-
nals require the submission of a completed CONSORT
checklist with stroke RCT manuscripts, and that this
becomes an integrated part of the peer-review assess-
ment. This may help make reporting standards uniform
across journals, and therefore rectify the disparity
between journals of high- and low-impact factors.
Continuous monitoring of reporting completeness2
and other sources of research waste27 will be necessary
and can be done by researchers in collaboration with
the REWARD Alliance (http://rewardalliance.net).
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